On February 27, 2020, Scott M. Lassman presented a webinar on recent developments affecting exclusivity for drugs and biological products. The webinar was hosted by FDANews.

Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation on October 2, 2019 in Washington, D.C.

Scott Lassman spoke on Biosimilars at the Food and Drug Law Institute’s Introduction to Biologics and Biosimilars Conference in Washington, D.C.

Scott Lassman spoke on First Amendment issues at the Food and Drug Law Institute's Advertising and Promotion for Medical Products Conference in Washington, D.C.

Scott Lassman spoke on the Biologics Price Competition and Innovation and Hatch-Waxman Acts at ACI's FDA Boot Camp in Boston.

Scott Lassman spoke on New Biosimilar Developments at the GRx+Biosims 2018 conference in Baltimore.

Scott Lassman spoke on biopharma regulatory issues at the NYC MedTech Conference in New York, NY. The conference was a medical technology life science forum hosted by the Consulate General of Hungary in New York.